The content of tumor necrosis factor (TNF)-a antigen and the bioactivity of soluble TNF receptor type II (sTNF-RII) in cerebrospinal fluid (CSF) from 29 patients with meningeal symptoms and fever were examined. Immunoreactive TNF was demonstrated in CSF from 4 of 7 patients with bacterial meningitis. In 3 of 8 patients with aseptic meningitis, CSF also contained TNF, but TNF bioactivity was confined to samples from patients with bacterial meningitis. Bioactive TNF was exclusively in high-performance liquid chromatography fractions containing 30-to 60-kDa proteins. Lipopolysaccharide induced down-regulation, possibly after shedding of granulocyte surface membrane TNF-RII. Consistently, there was a statistically significant correlation between sTNF-RII and CSF leukocyte counts. Bioactive TNF was found only in CSF containing> 1 ng of sTNF-RII/mL; samples without TNF bioactivity contained less sTNF-RII. Thus, a stabilizing effect of sTNF-RII on the oligomeric cytokine in vivo is plausible.
Tumor necrosis factor (TNF)-a is a potent biologic response modifier, and most leukocytes have the potential to synthesize and secrete the cytokine, although monocytes and macrophages are the main source [1, 2] . Two types ofTNF receptors (TNF-R) have been demonstrated, and the 75-kDa type II receptor (TNF-RII; CD120b) is inducible in most immune system cells (Leukocyte Differentiation Antigen Database version 1.10; available at NIH file transfer protocol site [balrog.nci.nih.govD.
The effects of TNF are numerous, ranging from cytotoxic and immune-stimulating effects to induction of disseminated intravascular coagulation and lethal shock [3] . Thus, the regulation ofTNF bioactivity represents a crucial balance, and several possible mechanisms have been suggested. Soluble TNF receptors (sTNF-R) are in human serum [4] [5] [6] and urine [7, 8] , and sTNF-R may buffer excess TNF released through binding of bioactive TNF, thereby blocking TNF bioactivity in vivo [5, 9, 10] . Another mechanism of down-regulation, the spontaneous decay of bioactive TNF oligomers into inactive monomers and polymeric protein, has been demonstrated in vitro [11] [12] [13] [14] and in vivo [15] . sTNF-R appear to stabilize otherwise unstable TNF in vitro [16, 17] and may serve as a carrier of bioactive TNF. In a previous study, we demonstrated the presence of bioactive and inactive TNF in cerebrospinal fluid (CSF) from meningitis patients [15] . That study also showed the in vivo correlation of high-molecular-weight TNF with inactive, but immunoreactive, TNF. This phenomenon might be caused by high-molecular-weight TNF/sTNF-R complexes and by formation of polymeric TNF. Alternatively, in vivo, sTNF-R may be a stabilizing factor of the unstable cytokine by binding to adjacent monomers in the homotrimer. This study was designed to test the in vivo significance of these possibilities.
Materials and Methods
Patients. Twenty-nine hospitalized patients with acute fever and meningeal symptoms entered the study. CSF and blood samples were drawn as part of the diagnostic program at admittance and before antibiotic treatment. Remaining CSF and serum (0.5-1.2 mL) were aliquoted and immediately frozen at -20°C. CSF samples were examined by microscopy and culture to detect bacterial infection, and glucose and protein contents were determined. Leukocytes in peripheral blood and CSF were counted. Of the 29 patients, 7 had bacterial and 8 had aseptic meningitis; 14 did not have meningitis (table 1) .
TNF ELISA. The ELISA was done as previously described [15] . Rabbit anti-human TNF antiserum was precipitated in saturated ammonium sulfate and stored at 5 mg/mL in PBS (pH 7.2) with 0.1% azide at 4°C. Detection antibodies were biotinylated using biotinamidocaproate-N-hydroxysuccinimide ester (Sigma, St. Louis). Catching antibodies were immobilized in 96-well microtiter plates at 10 j.Lg/mL (pH 9.6) overnight at 4°C. CSF and serum samples (l00 j.LL) were tested in duplicate in 1:2 and 1:4 dilutions. Chromatographic fractions were measured undiluted. The TNF standard was a gift of Biogent (Gent, Belgium) and was tested in the assay at 20-0.15 ng/mL in 7 serial dilutions. CSF and serum samples were incubated 2 h at 37°C; chromatographic fractions were incubated at 4°C overnight. Detection antibodies were added at 1 ,ug/mL for 60 min and after the mixture was washed, streptavidin-peroxidase (Dakopatts, Glostrup, Denmark) was added for another 60 min. Urea peroxide and o-phenyldiamine (Dakopatts) started the reaction, which was stopped in 1 M H 2S04 . Optical density was determined in a microtest reader at 492 nm. Mean optical density of the standard 0.15 ng/mL was higher than blank + 1.96 SD in all assays. Thus, the detection limit was 0.3 ng/mL at the dilutions used. The interassay coefficient of variation of 5 reanalyzed CSF samples (range, 2.7-4.5 ng/mL in the first assay) was 11%.
sTNF-RII interaction with TNF ELISA. Recombinant sTNF-RII (R&D Systems, Minneapolis) was incubated at 250 pg/mL (12.6 pM) with TNF at 1.25 ng/mL, and three 2-fold serial dilutions (24, 12, 6 , and 3 pM) were made. After 1 h at 37°C, TNF-sTNF-RII combinations were assayed as described above and compared with TNF alone.
Assay for TNF bioactivity. TNF bioactivity was determined in L-929 cells as described [18] . In brief, L-929 cell monolayers, seeded the day before, were overlaid with 2-fold serial dilutions of samples in MEM (GIBCO, Paisley, UK) with 10% heat-inactivated fetal calf serum, antibiotics, and actinomycin-D. The 96-well plates were incubated at 38.5°C for 18 h, and cells were fixed with formaldehyde, stained with crystal violet, and read for light absorbance at 600 nm. TNF titers were determined as the dilution resulting in 50% cytotoxicity and compared with a standard TNF titrated in the central row of each plate. The specific activity of standard TNF was 70 cytotoxic U/ng of TNF. The detection limit 
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of the assay was >4 U/mL (corresponding to 60 pg/mL). The coefficient of variation was 21%.
Chromatography. In 5 patients, the amount of CSF and the concentration of immunoreactive TNF sufficed for high-performance liquid chromatography (HPLC) analysis. CSF samples (90-150 J-lL) were subjected to HPLC using a Superose 12 column (Pharmacia, Uppsala, Sweden) at a flow rate of 0.75 mL of PBS/ min, and 475-J-lL fractions were sampled. CSF was centrifuged at 10,000 g before application, and 90-150 J.tL of CSF was loaded to the column. The elution peaks of aldolase (158 kDa), bovine serum albumin (67 kDa), ovalbumin (43 kDa), chymotrypsinogen (25 kDa), and ribonuclease (13.7 kDa; Sigma) were used to calibrate the HPLC. All fractions were immediately assayed for TNF by ELISA, stored at -20°C, and examined later (within 6 weeks) for TNF bioactivity by cytotoxicity assay.
125I_TNF displacement assay. Human T lymphocytes were isolated from venous blood by density centrifugation and sheep erythrocyte rosetting. The cells were cultured with 5 J-lg/mL phytohemagglutinin (Wellcome, Naerum, Denmark) for 3 days in RPMI 1640 (GIBCO) supplemented with 20% heat-inactivated human AB serum at 37°C and 10 6 cells/mL. At day 3, the lymphocytes were examined for TNF-R expression by flow cytometry (FACSort; Becton Dickinson, San Jose, CA) after staining with mouse monoclonal antibodies (MAbs) anti-TNF-RI and anti-TNF-RII (gift ofW. Lesslauer and M. Brockhaus, Hoffmann-LaRoche, Basel, Switzerland) and phycoerythrin-conjugated F(ab)2-rabbit antimouse immunoglobulins (Dakopatts) (figure 1 inset). Cells (5 X 105) from the same culture were resuspended in duplicate in 50 J-lL of CSF. 125I-labeled TNF tracer (5 pM) was added in 5 J-lL of PBS (pH 7.2), and binding was allowed for 16 h at 4°C. Cold recombinant TNF (Biogent) in 2-fold serial dilutions in TNF ELISA-negative and sTNF-RII ELISA-negative CSF was used as standard (figure 1). The detection range of the assay was 0.1-8 ng of TNF/mL.
TNF (ng/ml)
sTNF-RII ELISA. We used the Quantikine human sTNF-RII immunoassay (R&D Systems) to detect soluble p75 TNF-RII fragments in CSF as suggested by the manufacturer. In short, 200 J-lL of 1:10-and 1:40-diluted CSF was added to the anti-sTNF-RIIprecoated 96-well microtiter plate. After 2 h at room temperature, the plate was washed, and peroxidase-conjugated detection antibodies were added and incubated for 1 h. The chromogenic reaction used hydrogen peroxide and tetramethylbenzidine and was stopped in sulfuric acid. The plates were read in an automated microtest reader at 450 nm with wavelength correction set to 540 nm. The optical density in wells containing standard sTNF-RII (8-500 pg/mL) exhibited a linear correlation to added sTNF-RII concentrations. The detection limit of the assay was < 10 pg/mL, which corresponded to the detection of 100 pg of sTNF-RII/mL at the dilutions used.
Staining of TNF-RI and -RII in granulocytes. Granulocytes were isolated from whole blood by density-gradient centrifugation and lysing of contaminating red cells [19] . After stimulation with lipopolysaccharide (LPS; 100 ng/mL; Sigma) or 12-myristate-13-acetate phorbol ester (5 ng/mL; Sigma) at 37°C for 90 min, the granulocytes were stained with mouse MAbs (anti-TNF-RI and -RII) in 2% rabbit-serum in PBS (pH 7.2) or with rat MAb antihuman p80 TNF-R (TNF-RII; Genzyme, Cambridge, MA). Cells were washed and labeled with fluorescein isothiocyanate (FITC)-conjugated F(ab)2-rabbit anti-mouse immunoglobulins (Dakopatts) or with FITC-F(ab)2-rabbit anti-rat IgG (H +L; Zymed, San Francisco) followed by flow cytometry. Mean fluorescence of stimulated cells was compared with fluorescence in unstimulated coincubated cells.
Results

TNF immunoreactivity.
As shown in table 1, TNF was detected by ELISA in CSF of 7 of 15 patients with meningitis.
Spinal fluid leukocyte count (x10 6 cellsll) Correspondingly, bioactivity in CSF from patient 2 peaked at 12 mL, despite peak immunoreactivity in previous fractions (figure 3B); figure 3B also shows a representative elution profile of 3 CSF samples without bioactivity. Peak immunoreactivity corresponded to > 100 and <30 kDao Bioactivity was not detected in any fraction.
sTNF-RIl ELISA. Granulocytes down-regulated surface membrane TNF-RII density after LPS or phorbol ester stimulation (figure 4), whereas the p55 TNF-RI density was low in unstimulated cells and practically unaltered in stimulated cells (not shown). Therefore, we measured sTNF-RII levels in the CSF of patients with TNF ELISA-positive CSF samples and found a positive correlation of sTNF-RII concentration to CSF leukocyte count (F test, P < .01 by linear regression of logtransformed data; figure 5 ). Of interest, sTNF-RII concentrations were higher in CSF samples containing bioactive TNF, and bioactive TNF was confined to samples containing > 1 ng of sTNF-RII/mL (table 1) .
TNF/sTNF-RJI immunoreactivity in TNF ELISA. As shown in figure 6 , sTNF-RII influenced the immunoreactivity ofTNF at equimolar or higher concentrations of sTNF-R. In the presence of four times excess sTNF-RII, TNF ELISA reactivity was~60% of that of TNF alone.
The present study supports our previous findings ofbioactive and inactive forms of TNF in CSF of meningitis patients [16] and confirms the presence of high-molecular-weight inactive TNF antigen. Bioactive TNF elutes with an apparent molecular mass of~40 kDa, which is in agreement with the concept of a compact homotrimer [20, 21] . Although there is some controversy about the conformation of bioactive TNF [12, 14, 22] , there is little doubt that the TNF trimer is unstable at low and in vivo relevant concentrations [11] [12] [13] 16] . sTNF-R stabilizes the ligand in vitro, attenuating the decay of TNF to monomers and high-molecular-mass aggregates [16] . sTNF-R also may act as a "carrier" of bioactive TNF in vivo in a mouse model [10] .
This study demonstrated that sTNF-RII is elevated in CSF of patients with bacterial meningitis. The results are compatible with the notion that sTNF-RII is shed from LPS-stimulated granulocytes, as previously found in phorbol ester-and TNFstimulated granulocytes [23, 24] . The demonstration of bioactive TNF only in CSF that also contained> 1 ng/mL sTNF-RII suggests that the unstable ligand is stabilized by sTNF-R. A conformational, stabilizing change of the TNF trimer after receptor binding has been proposed [16] . Crystallography of the TNF-RI/TNF-,B complex has shown that two adjacent TNF- o Because only 1 (no. 19) of 14 nonmeningitis patients had detectable immunoreactive TNF in CSF, there was a significant difference between the 2 groups (X 2 test, .02 < P < .05). The TNF concentrations in CSF and serum did not correlate (not shown); however, TNF in CSF, when detected, tended to increase with increasing CSF leukocyte counts (figure 2). In bacterial meningitis patients, TNF was only demonstrated in patients with Neisseria meningitidis infections.
TNF bioactivity. TNF bioactivity in CSF was exclusively found in bacterial meningitis (table 1) . Thus, 4 patients (aseptic meningitis, 3; nonmeningitis, 1) had high levels of immunoreactive TNF in CSF but no bioactive TNF. Generally, TNF bioactivity was below that predicted by the TNF ELISA. Bioactivity in serum was observed in 1 patient (no. 18) who had meningococcemia without central nervous system engagement.
I-labeled TNF displacement.
Competition by TNF in CSF with 125I-Iabeled TNF binding to TNF-RII-presenting cells had good correlation (r = .98 by linear regression; F test, P < .01) with bioactivity (table 1), indicating that bioactive and inactive forms of TNF may be separated by their affinity for TNF receptors. In 1 patient with aseptic meningitis (no. 14), tracer displacement was observed in CSF in the absence ofbioactive TNF, which might have been caused by interaction of sTNF-R.
HPLC ofimmunoreactive TNF. CSF of 5 patients (nos. 2-4, 10, 13) with immunoreactive TNF was subjected to HPLC. Two CSF samples (nos. 2 and 3) contained significant bioactive TNF (>4 ng/mL), whereas the remaining 3 CSF samples contained <0.2 ng/mL. Figure 3A shows the elution profile of TNF in CSF from patient 3. A single peak of immunoreactivity at an elution volume of~12 mL, indicating an apparent molec- Elution volume (ml)
model offers an explanation for the paradox of simultaneous blocking ofTNF bioactivity [10] and stabilization ofbioactivity of the unstable ligand [16, this study]. The simultaneous binding of more than two TNF-RII molecules to one TNF-a molecule was also demonstrated by Pennica et al. [26] , and stabilization of trimeric TNF by soluble receptors might therefore leave additional receptor-binding site(s) to mediate bioactivity. In HPLC, bioactive TNF eluted with an apparent molecular mass of 30-40 kDa, and no TNF/sTNF-RII complexes (judged by shifts in molecular mass) were shown by TNF ELISA in the CSF of patient 3. Complex formation would be expected in the presence of 13 ng/mL sTNF-RII (650 pM) and bioactivity of 6 ng/mL TNF (120 pM bioactive and presumably receptorbinding ligand) in this CSF. The estimated ratio of bound-tofree ligand would be as follows: sTNF-RII/(TNF + apparent affinity constant) = 650 pM/(l20 pM + 0.3 nM) = 1.5. Thus, 60% of bioactive TNF was expected to be receptor bound, using the apparent affinity constant of TNF to sTNF-RII (K! = 0.3 nM) [26] . A possible explanation was found in the interference of sTNF-RIl with the TNF ELISA, since the increasing molar ratio of recombinant sTNF-RII to TNF caused a drop in the relative reactivity of TNF (figure 4). A previous study [27] also demonstrated the complex kinetics of TNF trimer dissociation and simultaneous association to antibodies recognizing the receptor-binding epitope of TNF and the interference of sTNF-RI with different TNF ELISAs. The TNF/sTNF-RII complexes in the chromatographic fractions might therefore escape detection, and the remaining bioactivity represent either [16] .
In conclusion, TNF and sTNF-RII levels are elevated in CSF in bacterial meningitis, and sTNF-RII appears to originate from shedding of granulocyte surface membrane TNF-RII. TNF bioactivity is confined to CSF containing> I ng/mL sTNF-RII, which suggests the sTNF-RII -mediated stabilization of bioactive TNF. 
